Caliper launches LabChip Dx for molecular diagnostics
31 Jan 2011
Caliper Life Sciences, Inc. has launched the LabChip Dx system
for clinical research laboratories developing molecular diagnostic
tests.
The LabChip Dx platform is now available in major markets around
the world and enables simultaneous analysis of up to ten different
analytes in a single sample.
The LabChip Dx system is the latest next-generation product platform
utilizing Caliper's microfluidic technology and intellectual
property, and delivers ease of use combined with rapid, accurate,
and cost-effective testing.
It is also capable of analyzing large numbers of multiplex samples
using minimal sample volume and avoids the need to further purify or
dilute diagnostic PCR products. The new system includes specific
identification, scoring and reporting software. The cost-effective
approach of Caliper's robust microfluidics technology has
contributed to its high rate of adoption among research laboratories
around the world.
"The market has been evolving to run multiple tests
simultaneously, and our LabChip Dx product is intended to address
this trend," said Kevin Hrusovsky, President and CEO of Caliper Life
Sciences. "This launch is the first step in our strategy to
penetrate the molecular diagnostics market. We are currently seeking
partners with unique molecular diagnostic content for validation and
clearance by regulatory agencies. Long-term, we intend to combine
our molecular diagnostics competencies with our recently acquired
multiplex tissue imaging technology to enter the emerging field of
companion diagnostics."